NCT05181748 Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders
| NCT ID | NCT05181748 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Genesis Athens Clinic |
| Condition | Poor Response to Ovulation Induction |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2019-01-23 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 100 participants in total. It began in 2019-01-23 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Autologous platelet rich plasma (PRP) intraovarian infusion may improve ovarian response to controlled ovarian stimulation as well as the hormonal profile of poor ovarian response infertile women subjected to intracytoplasmic sperm injection (ICSI) treatment.
Eligibility Criteria
Inclusion Criteria: Poor Ovarian Response according to Bologna Criteria (fulfilling 2 out of 3 of the following): 1. Age ≥ 40 years 2. AMH \< 1.1 ng/ml OR AFC \< 7 3. ≤ 3 oocytes with a conventional stimulation protocol * Discontinuation of any complementary/adjuvant treatment including hormone replacement and acupuncture, for at least three months prior to recruitment. * Willing to comply with study requirements Exclusion Criteria: * Any pathological disorder related to reproductive system anatomy * Cycle irregularities * Amenorrhea * Endometriosis * Adenomyosis * Fibroids and adhesions * Infections in reproductive system * Current or previous diagnosis of cancer in reproductive system * History of familiar cancer in reproductive system * Severe male factor infertility * Prior referral for Preimplantation Genetic Testing (PGT) -Ovarian inaccessibility -Endocrinological disorders (Hypothalamus- * Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome) * BMI\>30 kg/m2 or BMI\<18.5 kg/m2 * Systematic autoimmune disorders
Contact & Investigator
Agni Pantou, M.D
PRINCIPAL INVESTIGATOR
Genesis Athens Clinic
Frequently Asked Questions
Who can join the NCT05181748 clinical trial?
This trial is open to female participants only, aged 35 Years or older, up to 47 Years, studying Poor Response to Ovulation Induction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05181748 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05181748 currently recruiting?
Yes, NCT05181748 is actively recruiting participants. Contact the research team at agni.pantou@genesisathens.gr for enrollment information.
Where is the NCT05181748 trial being conducted?
This trial is being conducted at Athens, Greece.
Who is sponsoring the NCT05181748 clinical trial?
NCT05181748 is sponsored by Genesis Athens Clinic. The principal investigator is Agni Pantou, M.D at Genesis Athens Clinic. The trial plans to enroll 100 participants.